PrivatePulse·Companies·Celonis vs Deel

Celonis vs Deel: employee equity compared

Secondary market prices, valuation trajectory, equity structure, and liquidity outlook for employees choosing between Celonis and Deel.

Secondary market data updated monthly · Sources: Hiive, Forge
↑ Higher secondary premium

Celonis

SaaS · Germany · Founded 2011

Process mining and execution management platform that connects to ERP systems (SAP, Oracle) to map, analyse, and optimise business processes at scale.

Last primary round$13B · Series D (2021-06)
Secondary market$13.4B (+3% vs primary)
Annual revenue$0.4B ARR · +25% YoY (solid)
Headcount~3,000
Equity typeRSU
Illiquidity discount~22%
Last round leadT. Rowe Price
Liquidity outlook

IPO plausible 2027–2029 if growth trajectory holds. Liquidity may come via tender offer or strategic acquisition before listing.

Key equity angle

Predictable B2B ARR; RSU (no exercise cost); exit via IPO or strategic buyer

Deel

SaaS · San Francisco, CA · Founded 2019

Global payroll and compliance platform enabling companies to hire full-time employees and contractors in 150+ countries without setting up local entities.

Last primary round$12B · Series D (2022-10)
Secondary market$10.9B (-9% vs primary)
Annual revenue$0.4B ARR · +45% YoY (solid)
Headcount~3,200
Equity typeISO/NSO
Strike price range$28–$40 (depends on cohort)
Illiquidity discount~20%
Last round leadGeneral Atlantic
Liquidity outlook

IPO plausible 2027–2029 if growth trajectory holds. Liquidity may come via tender offer or strategic acquisition before listing.

Key equity angle

Predictable B2B ARR; ISO/NSO options; exit via IPO or strategic buyer

Key differences for employees

Equity structure

Celonis grants RSU — no exercise cost. Your equity vests and converts to cash or shares automatically at a liquidity event. Deel grants ISO/NSO with strike prices from $28–$40.

Secondary market premium

The secondary market is pricing Celonis at a +3% premium over its last primary round ($13B$13.4B). Deel trades at +-9% over its last round ($12B$10.9B). A higher secondary premium signals stronger investor demand and potentially better near-term liquidity for employees looking to sell.

Revenue and growth

Celonis runs at $0.4B ARR, growing +25% YoY (solid). Deel runs at $0.4B ARR, growing +45% YoY (solid). Revenue growth rate matters for equity because it drives the peer-multiple valuation — the method most correlated with exit multiples.

Liquidity timeline

Celonis: IPO plausible 2027–2029 if growth trajectory holds. Liquidity may come via tender offer or strategic acquisition before listing.

Deel: IPO plausible 2027–2029 if growth trajectory holds. Liquidity may come via tender offer or strategic acquisition before listing.

Calculate your specific grant

Enter your actual shares, equity type, and strike price. PrivatePulse calculates your personal equity value at both companies using 4 independent methods.

Frequently asked questions

Is Celonis or Deel a better company to work at for equity?
There's no universal answer — it depends on your risk profile, time horizon, and specific grant terms. Celonis at $13B and Deel at $12B offer very different risk/reward profiles. Use the calculator above to model your exact grant at each company.
How do I know if my Celonis or Deel equity is fairly priced?
Compare your grant's implied per-share value against the secondary market price. If investors are paying a premium on Hiive or Forge over the last primary round, that's a signal of strong demand. PrivatePulse shows you the gap between your 409A and what the secondary market says.
Can I sell my Celonis or Deel shares on the secondary market?
Secondary market transactions (Hiive, Forge, Caplight) require accredited investor status and your company's consent — most private companies have right-of-first-refusal (ROFR) provisions. Tender offers, when available, are typically the most accessible path to partial liquidity for employees.

More equity comparisons